Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Системный AL амилоидоз

Список литературы

  1. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Ed. by Swerdlow SH, Campo E, Harris NL, et al. International Agency for Research on Cancer. Lyon. 2017. P.585.
  2. Bhutani D, Lentzsch S. Diagnosis and management of systemic light chain AL amyloidosis. Pharmacol Ther. 2020; 214:107612.
  3. da Silva Filho MI, Försti A, Weinhold N, et al. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia. 2017; 31(8):1735-1742.
  4. Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018; 378: 241–249.
  5. Muchtar E, Dispenzieri A, Kumar SK, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017; 31(7):1562-1569.
  6. Bochtler T, Hegenbart U, Kunz C, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016; 128(4):594-602.
  7. Bochtler T, Hegenbart U, Kunz C, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib- based regimens. J Clin Oncol. 2015; 33:1371–1378.
  8. Perfetti V, Casarini S, Palladini G, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood. 2002; 100(3), 948–953.
  9. Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain associated amyloidosis (AL). Blood. 2003; 101(10), 3801–3808.
  10. Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271-2280.
  11. Rossi A, Voigtlaender M, Janjetovic S, et al. Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood Cancer J. 2017;7:e537.
  12. Hipp MS, Park SH, Hartl FU. Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol 2014; 24:506-14.
  13. Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010; 107(9):4188-93.
  14. Mishra S, Guan J, Plovie E, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013.1;305(1):H95-103
  15. Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010; 85: 232–238.
  16. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992; 79(7): 1817–1822.
  17. Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018; 2:1046–1053.
  18. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and Nterminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004; 22:3751–3757.
  19. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420–34
  20. Palladini G, Milani P, Merlini G. Management of AL Amyloidosis in 2020. Blood. 2020; 3;136(23):2620-2627
  21. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 20;30(9):989-95.
  22. Systemic Light chain amyloidosis. Version 1.2022. NCCN Clinical Practical Gaidenlines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf
  23. Palladini, G., Hegenbart, U., & Milani, P. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014; 124(15): 2325–2332.
  24. Gertz, M. A., Comenzo, R., Falk, R. H., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am. J. Hematol. 2005; 79(4), 319–328.
  25. Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. Hemasphere. 2020; 4(4):e454.
  26. Rahel S, Flammer Andreas J, Sabine G, et al. Expert recommendation from the swiss amyloidosis network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020; 150(49).
  27. Dispenzieri A, Kyle R, Merlini G, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009; 23:215–24.
  28. Bochtler T, Hegenbart U, Kunz C, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015; 33:1371–1378.
  29. Bochtler T, Hegenbart U, Kunz C, et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid. 2014; 21:9–17.
  30. Muchtar E, Dispenzieri A, Kumar SK, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017; 31:1562–1569.
  31. Sidana S, Larson DP, Greipp PT, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020; 34(5):1373-1382.
  32. Phelan D, Collier P, Thavendiranathan P. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012; 98(19): 1442–1448.
  33. Salinaro F, Meier-Ewert H K, Miller EJ. (Sep 1). Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017; 18(9):1057-1064.
  34. Fontana M, Pica S, Reant P, et alPrognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015; 132(16), 1570–1579.
  35. Banypersad SM, Sado DM, Flett AS., et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: An equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013; 6(1):34-9.
  36. Quarta, CC, Gonzalez-Lopez E, Gilbertson JA., et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017; 38(24):1905-1908.
  37. Kimmich C, Schönland S, Kräker S, et al. Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid. 2017; 24(1): 52–59.
  38. Gonzalez Suarez ML, Zhang P, Nasr S H., et al. The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry. Kidney International.2019; 96(4), 1005–1009.
  39. Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014; 99 (7): 1239–1247.
  40. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354(13):1362–9.
  41. Phull P, Sanchorawala V, Connors LH, et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018; 25(1):62–7.
  42. Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168 (2):186-206.
  43. mSMART. Treatment Guidelines: Amyloidosis. https://www.msmart.org/treatment-guidlines
  44. Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020; 95(7):848-860.
  45. Liu B, Bai M, Wang Y, et al. The efficacy and safety of bortezomib- based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis. Eur J Intern Med. 2019; 69:32-41.
  46. Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015; 126(5):612-5.
  47. Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 2014; 99: 743–750.
  48. Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan and dexamethasone for light chain amyloidosis. J Clin Oncol. 2020; 38(28): 3252-3260.
  49. Palladini G, Milani P, Foli A, et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia. 2014; 28(12):2311-6.
  50. Goodman HJB, Bradwell AR, Lachmann HJ, HawkinsP N. Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis. Blood (ASH Annual Meeting Abstracts). 2004; 104, 755A.
  51. Mollee P, Tiley C, Cunningham I, et al. A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. Br J Haematol. 2012; 157(6):766-9.
  52. Dietrich S, Schonland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010; 116, 522–528
  53. Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020. 2; 136(1):71-80.
  54. Kastritis E. Subcutaneus daratumumab + cyclophosphamide, bortezomib, and dexamethasone (Cybord) in patients with newly diagnosed light chain (AL) Amyloidosis: primary results from the phase 3 ANDROMEDA study. EHA Library. 06/14/20; 303396; LB2604.
  55. Kastritis E, Minnema C, Dimopoulos M, et al. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. (ASH Annual Meeting Abstracts). 2022; 2730.
  56. Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long term results from a phase 2 trial. Blood. 2012; 119:4860-4867.
  57. Cibeira MT, Oriol A, Lahuerta JJ, et al. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 2015; 170:804-813.
  58. Specter R, Sanchorawala V, Seldin DC, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant. 2011; 26:881-886.
  59. Dispenzieri A, Dingli D, Kumar SK, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010; 85:757-759.
  60. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010; 116:4777-4782.
  61. Sanchorawala V, Patel JM, Sloan JM, et al. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013; 98:789-792.
  62. Dinner S, Witteles W, Afghahi A, et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica. 2013; 98:1593-1599.
  63. Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011; 46:970-975.
  64. Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol. 2018; 36(13): 1323–9.
  65. Browning S, Quillen K, Sloan JM, Doros G, Sarosiek S, Sanchorawala V. Hematologic re lapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood. 2017; 130(11): 1383–6
  66. Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, et al. Fifteen Year Over- all Survival Rates after Autologous Stem Cell Transplantation for AL Amyloidosis. Am J Hematol. 2019; 94(9): 1020–6
  67. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, et al. Predictive fac- tors for hematopoietic engraftment after autologous peripheral blood stem cell trans- plantation for AL amyloidosis. Bone Marrow Transplant. 2005; 35(6): 567–75.
  68. Jimenez-Zepeda V, Duggan P, Neri P, et al. Bortezomib-maintenance for patients with AL amyloidosis: A single Center experience. Blood. 2017; 130(S1): 3151.
  69. Ozga M, Zhao Q, Benson DM, et al. AL amyloidosis: The effects of maintenance therapy on autologous stem cell transplantation outcomes. Blood. 2019; 134(S1): 2029.
  70. Российские клинические рекомендации «Множественная миелома» https://oncology association.ru/files/newclinicalguidelines/mnozhestvennaja_mieloma.pdf от 10.04.2020.
  71. Milani P, Merlini G. Monoclonal IgM-related AL amyloidosis. Best Pract Res Clin Haematol. 2016; 29(2):241-248.2016.
  72. Sachchithanantham S, Roussel M, Palladini G, et al. European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis. J Clin Oncol 2016; 34:2037e45.
  73. Palladini G, Foil A, Russo P, et al. Treatment of IgM-associated al amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011; 11(1):143-5.
  74. Milani P, Schönland S, Merlini G, et al. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood. 2018.;132(18):1988-199
  75. Manwani R, Sachchithanantham S, Mahmood S, et al. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood. 2018; 132(7):761-764.
  76. Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017; 130:597-605.
  77. Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol. 2012; 91:89-92.
  78. Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012; 119:5397-5404.
  79. Lentzsch S, Lagos GG, Comenzo RL, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: Results of a phase II study. J Clin Oncol . 2020; 38(13):1455-1462.
  80. Gertz MA, Falk RH, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985; 55(13 Pt 1):1645.
  81. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981. 63: 1285–1288.
  82. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008; 5(2):235-40.
  83. Feng D, Syed IS, Martinez M et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.Circulation. 2009; 119(18):2490–7.
  84. Gertz MA, Kyle RA, O'Fallon WM. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med. 1992; 152(11):2245-50.
  85. Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal AL amyloidosis following chemotherapy. J Clin Oncol. 2011; 29(6):674-81.
  86. Theodorakakou F, Fotiou D, Dimopoulos MA, Kastritis E. Solid Organ Transplantation in Amyloidosis. Acta Haematol. 2020; 143(4):352-364.
  87. Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med. 2001; 111(7):535-40.
  88. Poullos PD, Stollman N. Gastrointestinal Amyloidosis: Approach to Treatment. Curr Treat Options Gastroenterol. 2003; 6(1):17-25.
  89. Yam LT, Oropilla SB. Octreotide for diarrhea in amyloidosis. Ann Intern Med. 1991; 115(7):577.
  90. Wixner J, Suhr OB, Anan I. Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years. Expert Rev Gastroenterol Hepatol. 2018; 12(1):73–81.
  91. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma. Lancet Oncol. 2016; 17(8):e328-e3462016.
  92. Dittrich T, Kimmich C, Hegenbart U, Schönland SO. Prognosis and Staging of AL Amyloidosis. Acta Haematol. 2020; 143:388-399.
  93. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*